Angeles Wealth Management LLC Cuts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Angeles Wealth Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,126 shares of the company’s stock after selling 89 shares during the quarter. Angeles Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,461,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. U.S. Capital Wealth Advisors LLC raised its position in Novo Nordisk A/S by 0.6% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after acquiring an additional 90 shares during the period. Clarius Group LLC raised its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC raised its position in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after purchasing an additional 95 shares during the period. Montag A & Associates Inc. raised its position in shares of Novo Nordisk A/S by 1.0% during the 4th quarter. Montag A & Associates Inc. now owns 9,492 shares of the company’s stock valued at $982,000 after purchasing an additional 96 shares during the period. Finally, 9258 Wealth Management LLC increased its holdings in Novo Nordisk A/S by 4.0% in the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock valued at $260,000 after acquiring an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NVO shares. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $137.33.

View Our Latest Analysis on NVO

Novo Nordisk A/S Stock Up 0.7 %

Shares of NYSE:NVO traded up $0.93 during trading hours on Friday, hitting $143.33. The company’s stock had a trading volume of 2,777,695 shares, compared to its average volume of 4,570,466. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $143.73. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The company has a market capitalization of $643.20 billion, a price-to-earnings ratio of 49.10, a P/E/G ratio of 1.46 and a beta of 0.41. The firm’s fifty day moving average price is $129.44 and its 200 day moving average price is $118.72.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current year.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.